Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities
A Wegner - Immunotherapy, 2017 - Taylor & Francis
Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities
A Wegner - Immunotherapy, 2017 - kclpure.kcl.ac.uk
Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
[PDF][PDF] CAR-T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities
A Wegner - scholar.archive.org
CAR-T cells for the treatment of cancer and the future of preclinical models for predicting their
toxicities Anja Wegner1,2 1Kin Page 1 CAR-T cells for the treatment of cancer and the future …
toxicities Anja Wegner1,2 1Kin Page 1 CAR-T cells for the treatment of cancer and the future …
Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities
A Wegner - Immunotherapy, 2017 - search.proquest.com
Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities
A Wegner - Immunotherapy, 2017 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
[PDF][PDF] Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities
A Wegner - researchgate.net
She received an intravenous infusion of 10 billion third-generation CAR-T cells targeted
against this naturally occurring receptor [14]. Within 15 min, the patient developed …
against this naturally occurring receptor [14]. Within 15 min, the patient developed …
Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities
A Wegner - Immunotherapy, 2017 - discovery.ucl.ac.uk
Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
[PDF][PDF] CAR-T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities
A Wegner - core.ac.uk
CAR-T cells for the treatment of cancer and the future of preclinical models for predicting their
toxicities Anja Wegner1,2 1Kin Page 1 CAR-T cells for the treatment of cancer and the future of …
toxicities Anja Wegner1,2 1Kin Page 1 CAR-T cells for the treatment of cancer and the future of …
Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities.
A Wegner - Immunotherapy, 2017 - europepmc.org
Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical
trials, particularly in B-cell malignancies. However, reports of serious adverse events …
trials, particularly in B-cell malignancies. However, reports of serious adverse events …